192 related articles for article (PubMed ID: 26719579)
1. Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer.
Patterson AM; Kaabinejadian S; McMurtrey CP; Bardet W; Jackson KW; Zuna RE; Husain S; Adams GP; MacDonald G; Dillon RL; Ames H; Buchli R; Hawkins OE; Weidanz JA; Hildebrand WH
Mol Cancer Ther; 2016 Feb; 15(2):313-22. PubMed ID: 26719579
[TBL] [Abstract][Full Text] [Related]
2. An HLA-presented fragment of macrophage migration inhibitory factor is a therapeutic target for invasive breast cancer.
Hawkins O; Verma B; Lightfoot S; Jain R; Rawat A; McNair S; Caseltine S; Mojsilovic A; Gupta P; Neethling F; Almanza O; Dooley W; Hildebrand W; Weidanz J
J Immunol; 2011 Jun; 186(11):6607-16. PubMed ID: 21515791
[TBL] [Abstract][Full Text] [Related]
3. Identification of breast cancer peptide epitopes presented by HLA-A*0201.
Hawkins OE; Vangundy RS; Eckerd AM; Bardet W; Buchli R; Weidanz JA; Hildebrand WH
J Proteome Res; 2008 Apr; 7(4):1445-57. PubMed ID: 18345606
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of macrophage migration inhibitory factor in invasion of ovarian cancer].
Wu HM; Zhu SL; He LJ; Liu YH; Xie D
Ai Zheng; 2009 Oct; 28(10):1054-60. PubMed ID: 19799813
[TBL] [Abstract][Full Text] [Related]
5. Macrophage migration inhibitory factor as a potential prognostic factor in gastric cancer.
He LJ; Xie D; Hu PJ; Liao YJ; Deng HX; Kung HF; Zhu SL
World J Gastroenterol; 2015 Sep; 21(34):9916-26. PubMed ID: 26379396
[TBL] [Abstract][Full Text] [Related]
6. Detection of human leukocyte antigen biomarkers in breast cancer utilizing label-free biosensor technology.
Weidanz JA; Doll KL; Mohana-Sundaram S; Wichner T; Lowe DB; Gimlin S; Wawro Weidanz D; Magnusson R; Hawkins OE
J Vis Exp; 2015 Mar; (97):. PubMed ID: 25867039
[TBL] [Abstract][Full Text] [Related]
7. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
8. Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers.
Qian J; Wang Q; Xiao L; Xiong W; Xian M; Su P; Yang M; Zhang C; Li Y; Zhong L; Ganguly S; Zu Y; Yi Q
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38267222
[TBL] [Abstract][Full Text] [Related]
9. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.
Ramakrishna V; Ross MM; Petersson M; Gatlin CC; Lyons CE; Miller CL; Myers HE; McDaniel M; Karns LR; Kiessling R; Parmiani G; Flyer DC
Int Immunol; 2003 Jun; 15(6):751-63. PubMed ID: 12750359
[TBL] [Abstract][Full Text] [Related]
10. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
Wittman VP; Woodburn D; Nguyen T; Neethling FA; Wright S; Weidanz JA
J Immunol; 2006 Sep; 177(6):4187-95. PubMed ID: 16951384
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer.
Xu X; Wang B; Ye C; Yao C; Lin Y; Huang X; Zhang Y; Wang S
Cancer Lett; 2008 Mar; 261(2):147-57. PubMed ID: 18171602
[TBL] [Abstract][Full Text] [Related]
12. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
Takahashi T; Irie RF; Nishinaka Y; Hoon DS
Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820
[TBL] [Abstract][Full Text] [Related]
13. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
Correale P; Walmsley K; Nieroda C; Zaremba S; Zhu M; Schlom J; Tsang KY
J Natl Cancer Inst; 1997 Feb; 89(4):293-300. PubMed ID: 9048833
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides.
Peoples GE; Anderson BW; Fisk B; Kudelka AP; Wharton JT; Ioannides CG
Ann Surg Oncol; 1998 Dec; 5(8):743-50. PubMed ID: 9869522
[TBL] [Abstract][Full Text] [Related]
15. A novel DNA methyltransferase I-derived peptide eluted from soluble HLA-A*0201 induces peptide-specific, tumor-directed cytotoxic T cells.
Berg M; Barnea E; Admon A; Zavazava N
Int J Cancer; 2004 Nov; 112(3):426-32. PubMed ID: 15382068
[TBL] [Abstract][Full Text] [Related]
16. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
17. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.
Zhang H; Ye YL; Li MX; Ye SB; Huang WR; Cai TT; He J; Peng JY; Duan TH; Cui J; Zhang XS; Zhou FJ; Wang RF; Li J
Oncogene; 2017 Apr; 36(15):2095-2104. PubMed ID: 27721403
[TBL] [Abstract][Full Text] [Related]
18. Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes.
Fisk B; Anderson BW; Gravitt KR; O'Brian CA; Kudelka AP; Murray JL; Wharton JT; Ioannides CG
Cancer Res; 1997 Jan; 57(1):87-93. PubMed ID: 8988046
[TBL] [Abstract][Full Text] [Related]
19. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
20. Macrophage migration inhibitory factor expression in ovarian cancer.
Agarwal R; Whang DH; Alvero AB; Visintin I; Lai Y; Segal EA; Schwartz P; Ward D; Rutherford T; Mor G
Am J Obstet Gynecol; 2007 Apr; 196(4):348.e1-5. PubMed ID: 17403417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
